ASCO 2021 | Long term AEs in PSMA-TRT

Scott Tagawa, MD, MS, Weill Cornell Medical College, New York Presbyterian Hospital, NY, discusses long-term adverse events (AEs) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT). Preliminary studies suggest that long-term toxicity of PSMA-TRT is minimal; most AEs were attributed to alternative etiologies. Prof. Tagawa highlights the importance of including long-term follow-up in future trials. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 virtual meeting.